INTRODUCTION
Approximately one third of the world's population has serological evidence of past or present infection with HBV and 350-400 million people are chronic HBV surface antigen (HBsAg) carrier [1] .
Clinical course of chronic hepatitis B (CHB) is highly variable, ranging from an asymptomatic carrier state, to the development of cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC) [2] .
The prevalence of chronic hepatitis B virus infection is about 5% worldwide, but it differs between regions, 0.1%-02.0% in the United States and western Europe, 2.0%-8.0% in Mediterranean countries and Japan, and 8.0%-20% in southeast Asia and Sub-Saharan regions [3] .
Egypt has an intermediate HBV seroprevalence. HBV is classified into ten different genotypes (A-J) with different geographic distributions. Genotype D is the most prevalent in the Middle East. Limited data are available about HBV genotyping among Egyptian blood donors, particularly in Upper Egypt [4] .
Hepatitis B surface antigen (HBsAg) is considered a milestone in the research history of hepatitis B virus (HBV) and has been used for more than 40 years to confirm HBV infections [5] .
Recently, the relationship between serum HBsAg concentrations and HBV-DNA levels in hepatitis B patients who are positive for serum HBsAg and HBeAg was examined. Serum HBsAg concentration was related to HBV-DNA replication level [6] .
The architect HBsAg assay was the first to be approved and is widely used; it is a chemiluminescence microparticle immunoassay (CMIA) in which serum and anti-HBs-coated paramagnetic microparticles are combined [7] .
PATIENTS AND METHODS

Study design :
Cross-sectional study.
Patients :
We enrolled in the study 50 naive patients with Chronic hepatitis B virus, consecutively observed at Hepatology department at Mahalla Teaching Hospital in the period between May 2013 to October 2014, fulfilling all criteria detailed below.
Inclusion criteria :
Patients were included if they had a diagnosis of HBV based on HBsAg, HBeAg, HBV-DNA level, Liver biopsy. Male or female age 18 years or older. 
RESULTS
Fifty treatment naive patients with chronic hepatitis B (CHB) (persistent HBsAg positive for 6 months), recruited into the current study and divided into two groups; group (A) included patients with HBV DNA <2000 IU/ml, while group (B) included patients with HBV DNA ≥2000 IU/ml. Group (A) included 18 male and 7 female with their mean age (30.92 ± 5.64 years), while group (B) included 19 male and 6 female with their mean age (29.24 ± 4.25years). No significant statistical difference was founded between both groups regarding age and gender as shown in (Table 1) .
In group (A) the mean value ±SD of Hb was (14.12 ± 1.88), WBCs (5.65 ± 1.38) and for platelets was (198.72 ± 61.14), while in group (B) the mean value ±SD of Hb was (13.22+1.55), WBCs (5.89 ± 1.51) and platelets was (194.44 ± 59.69). No significant difference was found between both groups regarding the previously mentioned parameter, the mean value ±SD of total bilirubin in all groups was normal in group (A) (0.84 ± 0.30) and in group (B) (1.00 ± 0.34 mg/dl). The mean value ±SD of prothrombine time was normal in both groups. ALP values were not exceeding upper limit of normal in both groups, the mean value of ALP all groups was not significant. The mean value ±SD of AFP (alpha fetoprotein) in all groups was normal in group (A) (2.84 ± 2.18) and in group (B) (2.50 ± 1.41) as shown in (Table 2 ).
In both groups (A: HBV-DNA <2000 IU/ml, B: HBV-DNA ≥2000 IU/ml), there is strong correlation between HBsAg quantitation and HBV-DNA levels with mean value ±SD (155.28 ± 59.48) and (5359.52 ± 1754.90) respectively with strong statistical significant (p= 0.001) as shown in (Table 3 and Fig.3 ).
There is no correlation between HBV DNA level among all studied groups which (<2000 IU/ml or ≥2000 IU/ml) with histopathplogy grading and staging by METAVER scoring (p= 0.467) ( Table  4) .
In all studied patients with normal ALT (≤ 40 IU/Ml) (group (A1): 13 patients with HBV DNA level <2000 IU/ml & group (B1): 12 patients with HBV DNA level ≥2000 IU/ml), there is no statistical significant difference regarding histopathology by METAVER scoring ( fibrosis, p= 0.198 & activity, p=0.490) as shown in (Table 5) .
In all studied patients with persistently elevated ALT (>40 IU/ml) (group (A2): 12 patients with HBV DNA level <2000 IU/ml & group (B2): 13 patients with HBV DNA level ≥2000 IU/ml), there is no statistical significant difference with histopathology by METAVER scoring (fibrosis, p= 0.192 & activity, p=0.545) as shown in (Table  6 ).
The study of correlation between HBsAg quantitation and histopathology in all studied groups, showed there is statistical significance between fibrosis and HBsAg quantitation (r= 0.334, p=0.018) and no correlation with activity (r=0.017, p=0.905) by metaver scoring (fibrosis and activity) as shown in (Table 7 ).
In the studied group, a cut-off HBsAg titer of 1730.85 IU/ml could predict serum HBV DNA levels ≥ 2000 IU/ml with 100% sensitivity, 100% specificity, P value <0.001 and area under the curve (AUROC= 1.00), as shown in (Table 8 and The gold standard tool in assessing the stage of liver fibrosis is the histological evaluation of a liver biopsy. However, the procedure carries a moderate risk of complications, including bleeding and a small risk of death [12] .
This study aimed to evaluate correlation between HBsAg quantitation assay, histopathology and HBV-DNA level in chronic HBV patients.
This study involved 50 patients with chronic hepatitis B; 37 of them were males (74%) and 13were females (26%). This finding goes in line with El-Zayadi et al. who reported that (46 male and 6 female) with a median age of 37.5 years in evaluation of Egyptian Chronic Hepatitis B Patients and HBeAg-negative variant accounts for more than 80 % of CHB in Egypt [13] .
In this study there is no correlation between complete blood count and liver profile (serum bilirubin, serum albumin, AST, alkaline phosphatase, α-fetoprotein and prothrombine time) with HBV-DNA levels, this is in agreement with Koyuncure, who concluded that there was no correlation between HBV-DNA levels and biochemical tests [14] .
In this study there is strong correlation among the studied groups between HBsAg quantitation and HBV-DNA levels (p=0.001), this finding is supported by other studies. For example, in the study by Alghamdi et al., study had found statistically significant positive correlation between HBsAg titers and HBV DNA levels [15] .
In addition Primadharsini and Wibawa [16] had showed significant and strong correlation between quantitative HBsAg and HBV-DNA. Furthermore the study by Hong et al. [17] who concluded that in the 183 patients in whom serum HBsAg levels were quantified, there was a positive correlation between HBsAg quantitation and HBV DNA levels (0.0001). In contrast to this study ; Bai et al. had found that positive correlation between the severity of hepatic inflammation and fibrosis and serum HBV DNA level (P < 0.001) [26] . This association was found by Praneenararat et al. who concluded that serum HBV-DNA level >5.5 log IU/ml should predict a significant liver fibrosis in treatment naïve chronic hepatitis B that had indicated for liver biopsy [27] .
In this study, there is statistically significant positive correlation among all studied groups between HBsAg quantitation and fibrosis (P= 0.018). This is in agreement with Cheng et al. who had concluded that the correlation between advanced liver fibrosis and HBsAg level was a significant [28] . In this study, the validity of HBsAg titer in detecting cases with elevated HBV DNA level (≥ 2000 IU/ml) with HBsAg level at cut off point <1730.85 (IU/ml) with sensitivity, specificity (100% &100%, respectively) in all studied groups with P value <0.001 and Area under the curve (AUROC) = 1.
This study concluded that, there is strong significant correlation between HBsAg quantitation and HBV DNA levels, also there is correlation between HBsAg quantitation and fibrosis in contrast to no correlation between HBV DNA levels and histopathology ..
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